Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial

Urology

Volumn 81, Issue 6, 2013, Pages 1297-1302

  Schellhammer, Paul F ^b   Chodak, Gerald ^b   Whitmore, James B ^b   Sims, Robert ^b   Frohlich, Mark W ^b   Kantoff, Philip W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; DOCETAXEL; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; GLEASON SCORE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CANCER VACCINES; HEMOGLOBINS; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE EXTRACTS;

EID: 84878601468     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.01.061     Document Type: Article

References (24)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. G.L. Plosker Sipuleucel-T in metastatic castration-resistant prostate cancer Drugs 71 2011 101 108
3. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
4. E.J. Small, P.F. Schellhammer, and C.S. Higano Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 2006 3089 3094
5. Higano CS, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Presented at the 2009 Genitourinary Cancers Symposium. February 26-28, 2009: Orlando, FL. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=64&abstractID=20295. Accessed May 25, 2011.
6. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237
7. A.J. Armstrong, E.S. Garrett-Mayer, and Y.-C.O. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: ATAX327 Study Analysis Clin Cancer Res 13 2007 6396 6403
8. A. Macciò, C. Madeddu, and D. Massa Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia Blood 106 2005 362 367
9. G. Weiss Pathogenesis and treatment of anaemia of chronic disease Blood Rev 16 2002 87 96
10. B. Seruga, H. Zhang, and L.J. Bernstein Cytokines and their relationship to the symptoms and outcome of cancer Nat Rev Cancer 8 2008 887 899
11. T.F. Gajewski, M. Fuertes, and R. Spaapen Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment Curr Opin Immunol 23 2011 286 292
12. K. Töpfer, S. Kempe, and N. Müller Tumor evasion from T cell surveillance J Biomed Biotechnol 2011 2011 918471
13. T.L. Whiteside The tumor microenvironment and its role in promoting tumor growth Oncogene 27 2008 5904 5912
14. T.M. Beer, G.T. Bernstein, and J.M. Corman Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer Clin Cancer Res 17 2011 4558 4567
15. N.A. Sheikh, D. Petrylak, and C. dela Rosa Sipuleucel-T immune parameters correlate with overall survival in men with castrate-resistant prostate cancer Cancer Immunol Immunother 62 2013 137 147
16. N.A. Sheikh, E.J. Small, and D.I. Quinn Sipuleucel-T product characterization across different disease states of prostate cancer J Clin Oncol 30 2012 42
17. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
18. D.R. Berthold, G. Pond, and R. DeWit Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study [Meeting Abstracts] J Clin Oncol 25 18 suppl 2007 5005
19. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
20. C.J. Ryan, M.R. Smith, and J.S. de Bono Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 30 suppl 2012 abstr LBA4518
21. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
22. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
23. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
24. P.W. Kantoff, T.J. Schuetz, and B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105